Company
Louisville
Every investor coverage indicates participated in a round Jewish Hospital raised.
Companies Jewish Hospital acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Mark Slaughter | Director of the Heart Transplant and Mechanical Assist Device Program (former) | GBS Ventures (Mon 30 Aug 2010), GBS Ventures (Mon 10 Aug 2009), GBS Ventures (Mon 24 Nov 2008) |
Stories naming Jewish Hospital. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Sunshine Heart's chief executive reports to shareholders on the C-Pulse trial: halfway through its US feasibility study, first two minimally invasive implants completed and new hospitals in Australia, Canada and the US joining.
Sunshine Heart announces that two female patients at Louisville's Jewish Hospital are the first US women implanted with its C-Pulse heart assist system in an FDA-approved 20-patient feasibility trial.
Sunshine Heart reports the first two US implants of its C-Pulse heart assist device, performed at Ohio State under a 20-patient FDA-approved feasibility trial running across six American hospitals.
Sunshine Heart says a Kentucky hospital is the first US site cleared by an ethics board to join its FDA-approved C-Pulse heart failure trial, with patient enrolment expected once contracts are signed.
ASX-listed heart device maker Sunshine Heart has finished training clinicians at six US hospitals ahead of its C-Pulse feasibility trial, planned to start later in 2007.